688505.SH
复旦张江
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 8.38
−3.01%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 654.9M | 685.8M | 709.4M | 850.7M | 1.0B |
| Cost of Revenue | 65.5M | 69.3M | 61.2M | 70.6M | 84.1M |
| Gross Profit | 589.4M | 616.5M | 648.2M | 780.1M | 947.1M |
| Operating Expenses | |||||
| R&D Expense | 326.9M | 357.9M | 314.2M | 243.8M | 226.9M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 39.3M | 40.4M | 41.7M | 42.9M | 44.9M |
| Selling & Marketing Expense | 383.5M | 395.1M | 299.3M | 383.6M | 554.6M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 756.7M | 799.1M | 657.6M | 671.9M | 824.4M |
| Cost and Expenses | 822.3M | 868.4M | 718.8M | 742.5M | 908.5M |
| Operating Income (EBIT) | (150.4M) | (155.4M) | 2.4M | 97.1M | 133.3M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (150.8M) | (155.9M) | 5.5M | 97.5M | 132.3M |
| Income Tax Expense | — | 1.9M | (34.0M) | (10.9M) | (5.0M) |
| Bottom Line | |||||
| Net Income | (152.4M) | (157.4M) | 39.7M | 108.6M | 138.0M |
| Earnings from Cont. Ops | (152.7M) | (157.7M) | 39.4M | 108.4M | 137.3M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (152.4M) | (157.4M) | 39.7M | 108.6M | 138.0M |
| Per Share | |||||
| Basic EPS | — | (CN¥0.15) | CN¥0.04 | CN¥0.11 | CN¥0.13 |
| Diluted EPS | — | (CN¥0.15) | CN¥0.04 | CN¥0.11 | CN¥0.13 |
| Revenue Per Share | — | — | — | — | — |
| Shares | |||||
| Basic Shares Outstanding | — | — | — | — | — |
| Diluted Shares Outstanding | — | — | — | — | — |
| Profitability Metrics | |||||
| EBITDA | — | (82.8M) | 76.7M | 151.3M | 207.3M |
| D&A | — | 72.6M | 74.3M | 54.2M | 74.1M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026